Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Puma Biotechnology (PBYI) Gross Profit (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Gross Profit for 9 consecutive years, with $52.3 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gross Profit rose 15.88% year-over-year to $52.3 million, compared with a TTM value of $170.2 million through Dec 2025, up 2.5%, and an annual FY2025 reading of $170.2 million, up 2.5% over the prior year.
  • Gross Profit was $52.3 million for Q4 2025 at Puma Biotechnology, up from $42.3 million in the prior quarter.
  • Across five years, Gross Profit topped out at $70.8 million in Q4 2022 and bottomed at $33.0 million in Q1 2024.
  • Average Gross Profit over 5 years is $44.7 million, with a median of $42.8 million recorded in 2023.
  • Peak annual rise in Gross Profit hit 62.92% in 2022, while the deepest fall reached 49.15% in 2022.
  • Year by year, Gross Profit stood at $43.5 million in 2021, then surged by 62.92% to $70.8 million in 2022, then crashed by 32.42% to $47.9 million in 2023, then decreased by 5.64% to $45.2 million in 2024, then increased by 15.88% to $52.3 million in 2025.
  • Business Quant data shows Gross Profit for PBYI at $52.3 million in Q4 2025, $42.3 million in Q3 2025, and $40.1 million in Q2 2025.